Synonyms: FBP, Folbp1
Farletuzumab (Anti-FOLR1) is a humanized monoclonal antibody with high affinity for FRα. It is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer. MW: 144.12 KD
| Featured Inhibitors | Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933 |
|---|
| Description |
Farletuzumab (Anti-FOLR1) is a humanized monoclonal antibody with high affinity for FRα. It is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer. MW: 144.12 KD
|
|---|
| CAS No. | 896723-44-7 |
|---|---|
| Molecular Weight | 144.12 kDa |
| Isotype | Human IgG1 |
| Source | CHO |
| Purification | AKTA |
| Sterility | 0.2 μM filtered |
| Formulation | 100 mM Pro-Ac, 20mM Arg, pH5.0 |
| Storage (From the date of receipt) |
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|---|
| NCT04300556 | RECRUITING | Drug: Farletuzumab ecteribulin|Drug: Prednisone|Drug: Predni | Solid Tumor | Eisai Inc. | 2020-08-06 | PHASE1; PHASE2 |
| NCT05577715 | TERMINATED | Drug: MORAb-202 | Carcinoma, Non-Small-Cell Lung | Bristol-Myers Squibb | 2022-11-14 | PHASE2 |
| NCT05613088 | COMPLETED | Drug: MORAb-202|Drug: Paclitaxel|Drug: Pegylated Liposomal D | Neoplasms, Ovarian | Bristol-Myers Squibb | 2023-02-01 | PHASE2 |
| NCT03386942 | COMPLETED | Drug: Farletuzumab Ecteribulin | Solid Tumors | Eisai Inc. | 2017-11-28 | PHASE1 |
| NCT02289950 | COMPLETED | Drug: Farletuzumab|Drug: Placebo | Platinum-Sensitive Ovarian Cancer in First Relapse | Eisai Inc. | 2015-03-19 | PHASE2 |
| NCT01203618 | WITHDRAWN | Drug: Farletuzumab | Resectable, Non-functioning Pituitary Adenoma | Morphotek | 2011-02 | PHASE2 |
(data from https://clinicaltrials.gov, updated on 2026-06-04)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.